menu-hamburger-svgrepo-com

WEBINAR REPLAY

WEBINAR REPLAY: Biologics & Biosimilars

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Presented by

:
:
DAYS
HRS
MINS

BOOKINGS

Dna,Double,Helix,Graphic,Illustration,Pharmaceutical,Research,Into,Genetic,Molecular

To watch the replay, click here: https://bit.ly/ReplayWebinar5April 

To request your certificate of attendance from watching the replay, email john.woodford@newmedia.co.za 

WHAT IS A BIOLOGIC? 

A biopharmaceutical, also known as a biologic medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi-synthesised from biological sources. 

While biologics have revolutionised therapy of several immune mediated inflammatory diseases (IMIDs) like rheumatoid arthritis, systemic lupus erythematosus, other connective tissue diseases (vasculitis, inflammatory muscle disease, Sjögren’s syndrome), and the spondyloarthropathies (axial spondyloarthropathy, psoriatic arthritis), unfortunately they are so expensive that access to them worldwide is limited. 

Of the over 55 million people in SA, approximately 1% are affected by rheumatoid arthritis, 0.5-1% are affected by spondylarthritis, and 0.5% are affected by other autoimmune disease. “That’s a large amount of people, but unfortunately, we have a really low rate of using biologics simply because we’re a resource constrained country. Probably at least 10% of affected patients would benefit from, and really need a biologic,” said Dr Elsa van Duuren. “It’s a large number of patients, probably in excess of 100 000 individuals. At present, only 6 000 of those are on biologics.” 

THE ROLE OF BIOSIMILARS 

Fortunately, as patents on originators expire, biosimilar development has been occurring. “We don’t talk about generics when it comes to biologics because there are some differences. It’s what the WHO calls a similar biotherapeutic product (SBP), or biosimilar,” explained Dr Van Duuren. Describing them as ‘game changers’ she listed the following potential benefits of biosimilar medicines: 

  • More options for healthcare providers and patients. 
  • Access to biologic products earlier in disease process. 
  • Switch from costly originator versions to biosimilar alternatives. 
  • Biosimilar use expected to save billions around the world. 

CHALLENGES FOR A BIOSIMILAR MEDICINE 

Biologic medicines are large complex molecules which may be difficult to fully characterise. The amino acid sequence is expected to be the same and only small differences in the microheterogeneity pattern are acceptable. 

Biologicals require highly specialised and controlled manufacturing processes. However, biosimilars manufacturers do not have access to all necessary manufacturing information on the originator product. As a result, minor differences in the manufacturing process may affect the pharmacokinetics, pharmacodynamics, efficacy and/or safety. 

EVALUATION OF BIOSIMILARS 

As a result, unlike generics, biosimilars have to go through very rigorous testing. Dr Van Duuren explained that Sahpra has given very similar guidance to the WHO guidelines on evaluation of SBPs. Decision making regarding the licensing of SBPs should be based on scientific evidence. The onus is on a manufacturer of a SBP to provide the necessary evidence to support all aspects of an application for licensing. As with any drug development program, the development of a SBP involves a stepwise approach starting with characterisation and evaluation of quality attributes of the product and followed by non-clinical and clinical studies. 

“Evidence must be provided that the biosimilar is highly similar to the registered medicine in quality, potency, purity, safety, and efficacy,” said Dr Van Duuren. “So, they go through the same type of clinical studies that the originator product went through – preclinical studies, toxicity studies, phase 2 randomised controlled trials with dose comparisons, and phase 3 double blind randomised controlled trials. The only sort of short-cut that biosimilars are allowed is that they’re allowed to do a study in one indication and extrapolate the efficacy data to another indication.” 

“The bottom line is we really have good data to support the use of biosimilars and that’s because they have to go through such vigorous testing and trials. We’re already seeing that biosimilars are going to offer a lot more benefits to a lot more patients.” 

Sign in to access full articles and earn your CPD points.

Clinical and CPD content is compiled by Key Opinion Leaders and our expert medical editors.

Already registered? Login here

Past webinars

Suggested clinical & CPD content

Related articles

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Please check your email for an activation mail. Click the activation link to activate your account

Stay up to date

Search for anything across CPD, webinars and journals
idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! You have successfully booked your seat.

All webinar details will be emailed to your email address.

Did you know, you can book future webinars with a single click if you register an account with Medical Academic.

Congratulations! Your account was successfully created.

Your webinar seat has been booked and all webinar details will be emailed to your registered email address

Why not register for Medical Academic while booking your seat for this webinar?

Future Medical Academic webinars can be booked with a single click, all with a Medical Academic account… and it’s FREE.

Book webinar & create your account

* (Required)

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Thank you for registering. You can now log in to your account.

Create your account

* (Required)

Login with One Time Pin (OTP)

Enter your registered email address to receive an OTP

A verification code will be sent to your email address. Please ensure that admin@medicalacademic.co.za is on your safe sender list.

We've sent your OTP
Welcome to Medical Academic​

Get the most out of Medical Academic by telling us your occupation. This helps us create more great content for you and the community.